Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17954336 | 0.97 | HPGD (0.44) | HPGDCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18165314 | 0.80 | HPGD (0.60) | HPGDCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17955274 | 0.80 | MEN1 (0.37) | HPGDMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17955249 | 0.79 | TERT (0.37) | HPGDMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL17955291 | 0.79 | KMT2A (0.36) | HPGDMEN1KMT2AMAPTKDM4E | |
| SCHEMBL16624730 | 0.78 | SMN1; SMN2 (0.48) | HPGDTDP1MAPTKDM4EALDH1A1 | |
| SCHEMBL17955290 | 0.78 | TERT (0.38) | MEN1KMT2ATP53 | |
| SCHEMBL16627109 | 0.78 | CYP1A2 (0.47) | HPGDCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL21610293 | 0.77 | TDP1 (0.43) | HPGDCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17954342 | 0.76 | HPGD (0.56) | HPGDCYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | HPGD 4793/4885CYP1A2 4882/4885CYP3A4 4884/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | HPGD 4793/4885CYP1A2 4882/4885CYP3A4 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.